AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-07. Numbers and descriptions here follow the published literature rather than marketing material.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
=== As larvae === In studies, T. molitor larvae show an incubation period of seven to eight days and a period of three to four days for the first instar. After the first instar, there is significant variation for the number of days in each instar period, though variation may be due to malnutrition or pathogens. Before emergence, most larvae typically go through 15 to 17 instars, with very few larvae going through the 19 to 20 instars. The body length of the larvae gradually increases with each successive instar, reaching maximum length at the 17th instar. The body length decreases beyond the 17th instar. Pupation occurs after the 14th instar, with most larvae showing total pupation between the 15th and 17th instars. Larvae are white in the first instar and gradually turn brown after the second instar.
The redox reaction rate is limited by the formation of a favorable activated complex involving an oxo-bridge between the perchlorate anion and the metallic cation. It depends on the molecular orbital rearrangement (HOMO and LUMO orbitals) necessary for a fast oxygen atom transfer (OAT) and the associated electron transfer as studied experimentally by Henry Taube (1983 Nobel Prize in Chemistry) and theoretically by Rudolph A. Marcus (1992 Nobel Prize in Chemistry), both awarded for their respective works on the mechanisms of electron-transfer reactions with metal complexes and in chemical systems. In contrast to the Fe2+ cations which remain unoxidized in deaerated perchlorate aqueous solutions free of dissolved oxygen, other cations such as Ru(II) and Ti(III) can form a more stable bridge between the metal centre and one of the oxo groups of ClO−4. In the inner sphere electron transfer mechanism to observe the perchlorate reduction, the ClO−4 anion must quickly transfer an oxygen atom to the reducing cation. When it is the case, metallic cations can readily reduce perchlorate in solution. Ru(II) can reduce ClO−4 to ClO−3, while V(II), V(III), Mo(III), Cr(II) and Ti(III) can reduce ClO−4 to Cl−. Some metal complexes, especially those of rhenium, and some metalloenzymes can catalyze the reduction of perchlorate under mild conditions. Perchlorate reductase (see below), a molybdoenzyme, also catalyzes the reduction of perchlorate. Both the Re- and Mo-based catalysts operate via metal-oxo intermediates.
Carbonylation of alcohols as illustrated by the Cativa process for the production of acetic acid. Formic acid is prepared by a different carbonylation pathway, also starting from methanol. Oxidation of aldehydes with air using cobalt and manganese catalysts. The required aldehydes can be obtained from alkenes by hydroformylation. Oxidation of hydrocarbons using air. For simple alkanes, this method is inexpensive but not selective enough to be useful. Allylic and benzylic compounds undergo more selective oxidations. Alkyl groups on a benzene ring are oxidized to the carboxylic acid, regardless of its chain length. Benzoic acid from toluene, terephthalic acid from para-xylene, and phthalic acid from ortho-xylene are illustrative large-scale conversions. Acrylic acid is generated from propene. Hydrocarboxylation of alkenes. This method is effective for alkenes that generate secondary and tertiary carbocations, e.g. isobutylene to pivalic acid. In the Koch reaction, the addition of water and carbon monoxide to alkenes or alkynes is catalyzed by strong acids. Hydrocarboxylations involve the simultaneous addition of water and CO. Such reactions are sometimes called "Reppe chemistry." HC≡CH + CO + H2O → CH2=CH−CO2H Hydrolysis of esters. Triglycerides, obtained from plant or animal oils, are precursors to long-chain carboxylic acids are related to soap making. Fermentation of ethanol. This method is used in the production of vinegar. Carbonation, such as the Kolbe–Schmitt reaction as a route to salicylic acid, precursor to aspirin.
== Newtonian vs Non-Newtonian fluids == A Newtonian fluid (named after Isaac Newton) is defined to be a fluid whose shear stress is linearly proportional to the velocity gradient in the direction perpendicular to the plane of shear. This definition means regardless of the forces acting on a fluid, it continues to flow. For example, water is a Newtonian fluid, because it continues to display fluid properties no matter how much it is stirred or mixed. A slightly less rigorous definition is that the drag of a small object being moved slowly through the fluid is proportional to the force applied to the object. (Compare friction). Important fluids, like water as well as most gasses, behave—to good approximation—as a Newtonian fluid under normal conditions on Earth. By contrast, stirring a non-Newtonian fluid can leave a "hole" behind. This will gradually fill up over time—this behavior is seen in materials such as pudding, oobleck, or sand (although sand isn't strictly a fluid). Alternatively, stirring a non-Newtonian fluid can cause the viscosity to decrease, so the fluid appears "thinner" (this is seen in non-drip paints). There are many types of non-Newtonian fluids, as they are defined to be something that fails to obey a particular property—for example, most fluids with long molecular chains can react in a non-Newtonian manner.
Sources: en.wikipedia.org
Herbal medicine (also called herbalism, phytomedicine or phytotherapy) is the study of pharmacognosy and the use of medicinal plants, which are a basis of traditional medicine. Scientific evidence for the effectiveness of many herbal treatments remains limited, prompting ongoing regulatory evaluation and research into their safety and efficacy. Standards for purity or dosage are generally not provided. The scope of herbal medicine sometimes includes fungal and bee products, as well as minerals, shells and certain animal parts. Paraherbalism is the pseudoscientific use of plant or animal extracts as medicine, relying on unproven beliefs about the safety and effectiveness of minimally processed natural substances. Herbal medicine has been used since at least the Paleolithic era, with written records from ancient Sumer, Egypt, Greece, China, and India documenting its development and application over millennia. Modern herbal medicine is widely used globally, especially in Asia and Africa. Traditional medicine systems involve long-standing, culturally-embedded practices using local herbs, animal products, and spiritual elements. These systems have influenced and contributed to modern pharmacology. Herbalists believe that plants, having evolved defenses against environmental stressors, produce beneficial phytochemicals, often extracted from roots or leaves, that can be used in medicine.
As a result, Sir Robert Fraser of the ITA declared that the only acceptable forms of advertising on ITV were those clearly intended to promote sales of the product or services in question, and that "[advertising] designed to influence public opinion during a takeover battle or a campaign against nationalization on behalf of private enterprise — however well disguised — would in future be disallowed." In 1994, Lyons Original Coffee hired the advertising agency Duckworth Finn Grubb Waters (DFGW), who created an innovative UK television advert that aimed "to turn a commercial break into a coffee break." Employing an interactive "datablast" technique, the advert depicts scans of 30 pages from women's magazines, such as Cosmopolitan, Elle and Good Housekeeping, displayed at the rate of five frames a second, and the advert invites viewers to record the commercial on a VCR, play it back and then repeatedly pause it, one frame at a time, to read the pages while sat with a cup of Lyons coffee, with the advertisement providing "30 minutes of magazine 'reading' in 30 seconds." Considered groundbreaking, the advertisement premiered on Channel 4 on 7 November 1994, and was compared other nascent forms of interactive advertising from the same year, such as HHCL's commercials for the Mazda 323, one of which similarly invited viewers to record it and play it back and pause at specific moments, allowing to read otherwise momentary information about the car and a competition to win one.
National Fireproofing Contractors Association https://www.nfca-online.org/ Structural Fire Protection - American Institute of Steel Construction https://www.aisc.org/globalassets/modern-steel/archives/2002/12/2002v12_fire.pdf NFPA Standards Archived 2011-07-28 at the Wayback Machine
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.